Navigation Links
Johnson & Johnson (China) Investment Ltd. Acquires Guangzhou Bioseal Biotechnology Co., Ltd.
Date:5/3/2012

GUANGZHOU, China, May 3, 2012 /PRNewswire-Asia/ -- Johnson & Johnson (China) Investment Ltd. today announced it has acquired Guangzhou Bioseal Biotechnology Co., Ltd. (Bioseal) a privately held biopharmaceutical company specializing in the design, development and commercialization of a porcine plasma-derived biologic product for controlling bleeding during surgery. The acquisition was completed after obtaining all necessary Chinese Government approvals. Financial terms of the transaction are not being disclosed.

"This transaction reinforces our commitment to China and delivering innovative medical device solutions to the Chinese market," said Xie Wen Jian President of Johnson & Johnson Medical China. "We are very pleased to add the BIOSEAL™ brand to our growing portfolio of hemostasis products in China and we look forward to working with our new Bioseal colleagues to bring their innovative products to more physicians and patients."

Bioseal manufactures a porcine-derived fibrin sealant, BIOSEAL™, currently the only porcine plasma-derived fibrin sealant approved for use in China. Fibrin sealants are used by surgeons as an adjunct to hemostasis for use in patients undergoing surgery, when control of bleeding by standard surgical techniques is ineffective or impractical.

Bioseal will work closely with Ethicon, Inc., a Johnson & Johnson Company, which offers the world's most complete line of absorbable hemostats with a commitment to advancing the future of biosurgery beyond hemostasis, to seal leaks, join structures and enhance healing. Ethicon biosurgery brands already on the market in China include SURGICEL® and SURGIFLO®.

"By adding Bioseal to the existing line of Ethicon hemostasis products sold in China, we aspire to shape the broader biosurgery market in Asia by providing physicians and their patients with an even greater variety of innovative and clinical-based solutions to address bleeding, sealing and leaking challenges," said Michael del Prado, Company Group Chairman, Johnson & Johnson Medical Asia Pacific. 

This is the first acquisition in the medical device industry for Johnson & Johnson (China). The corporation has been doing business in China for more than 25 years, including establishing a new innovation center in China last year to design and develop medical devices and diagnostic products specifically for Asia's emerging markets. This acquisition reinforces our long-standing commitment to providing medical solutions in Asia that help to improve the standard of health care for millions of people in the region.

The acquisition of Bioseal will complement Ethicon's existing biosurgery portfolio and will allow the business to immediately enter the fibrin sealant market in China, broaden product offerings and create an opportunity to increase global reach by introducing advanced biologic solutions that meet the various needs of more physicians and patients, throughout Asia and around the world.

About Johnson & Johnson (China) Investment Ltd.

Johnson & Johnson (China) Investment Ltd. is a foreign investment entity established in China by Johnson & Johnson in 1998. For more information about Johnson & Johnson and its operating units in China, please visit www.jnj.com.cn.

About Ethicon, Inc.

Ethicon, Inc. is a trusted, world-wide leader in surgical care. For over a century, Ethicon has continuously introduced innovations in wound closure, general surgery, wound management, biosurgicals, women's health and urology, aesthetic medicine and ENT solutions that fulfill the Company's vision: Restoration of body and of life.


'/>"/>
SOURCE Johnson & Johnson (China) Investment Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Johnson & Johnson to Provide Webcast Presentation of XARELTO® (rivaroxaban) Phase 3 Clinical Data Presented at the American College of Cardiologys Annual Scientific Sessions
2. CNJ Enterprises: DePuy ASR Hip Implant Recall Large Contributor to Johnson & Johnsons $2.9 Bil Charge for 4th Quarter 2011
3. Johnson & Johnson Reports 2011 Fourth-Quarter and Full-Year Results:
4. Johnson & Johnson to Host Analyst Meeting to Discuss Fourth-Quarter and Full-Year 2011 Financial Results
5. Johnson & Johnson to Participate in the Piper Jaffray 23rd Annual Health Care Conference
6. Johnson & Johnson Reports 2011 Third-Quarter Results
7. Johnson & Johnson to Host Analyst Conference Call on Third-Quarter Results
8. Boston Scientific Announces Favorable Appellate Court Ruling Affirming Non-Infringement of Johnson & Johnson Patent
9. McNEIL-PPC, Inc. Acquires Full Ownership of the Johnson & Johnson-Merck Consumer Pharmaceuticals Co. Joint Venture
10. Johnson & Johnson Makes Strong Progress in First Year of Initiative to Improve Health of Millions of Women and Children in the Developing World
11. Johnson & Johnson to Participate in Morgan Stanley Global Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... April 27, 2016 Shire plc (LSE: ... Poulton , Chief Financial Officer, will present at the Deutsche ... MA on Wednesday, May 04, 2016, 10:00 am ... be available on the Presentations and Webcasts section of Shire,s ... the webcast will be available on this same website for ...
(Date:4/27/2016)... 27, 2016 Oasmia Pharmaceutical ... of a new generation of drugs within human ... results for Paclical/Apealea in the Phase III study ... epithelial ovarian cancer. These preliminary results showed non-inferiority ... with carboplatin versus Taxol in combination with carboplatin. ...
(Date:4/27/2016)... , April 27, 2016 ... reach USD 2.06 billion by 2022, according to ... Increasing consumer awareness towards a healthy lifestyle is ... seven years.      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ... coupled with rising health treatment expenditure has urged ...
Breaking Medicine Technology:
(Date:4/28/2016)... ... April 28, 2016 , ... ... the open availability of a new CDISC standard, Clinical Trial Registry (CTR) ... trials. This innovative standard will make it possible to build applications that ...
(Date:4/28/2016)... ... April 28, 2016 , ... Trinity Health, one ... a leading force in the fight to reduce tobacco use and its deadly ... can help reduce tobacco use. The initiative brings together two organizations committed to ...
(Date:4/28/2016)... ... April 28, 2016 , ... In 2011, TIME magazine named Herr the “Leader ... biomechatronics, technology that marries human physiology with electromechanics. He continues that work as Director ... Founder of BionX , a leader in the field of prosthetic devices. , ...
(Date:4/28/2016)... ... April 28, 2016 , ... Cognizin® Citicoline is one of ... in the Healthy Ageing category, Cognizin® is being considered for this prestigious honor ... can include everything from antioxidants, lipids, proteins, and botanicals. NutraIngredients will choose a ...
(Date:4/28/2016)... ... ... Card reminds us that May is National Stroke Awareness Month. According to the Centers ... in the United States; someone has one every 40 seconds. Annually, almost 800,000 strokes ... old. A stroke is when blood flow to the brain is blocked or when ...
Breaking Medicine News(10 mins):